| |
Latest 10 SEC filings (by transaction date) for EXEL within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Mar 25/24 | Mar 21/24 | Garber Alan M | Direct Ownership | Option (right to buy) | M - Exercise or conversion exempt under rule 16b-3 | -23,491 | |
Mar 25/24 | Mar 21/24 | Garber Alan M | Direct Ownership | Common Stock | S - Open market or private sale | -19,205 | $24.01 |
Mar 25/24 | Mar 21/24 | Garber Alan M | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 23,491 | $19.57 |
Feb 27/24 | Feb 23/24 | Peterson Amy C. | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 82,121 | |
Feb 27/24 | Feb 23/24 | Aftab Dana | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 63,350 | |
Feb 27/24 | Feb 23/24 | Morrissey Michael | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 241,670 | |
Feb 27/24 | Feb 23/24 | Senner Christopher J. | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 82,121 | |
Feb 27/24 | Feb 23/24 | Hessekiel Jeffrey | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 63,350 | |
Feb 27/24 | Feb 23/24 | Haley Patrick J. | Direct Ownership | Common Stock | S - Open market or private sale | -47,020 | $21.45 |
Feb 27/24 | Feb 23/24 | Haley Patrick J. | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 63,350 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for EXEL within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Mar 25/24 | Mar 21/24 | Garber Alan M | Direct Ownership | Option (right to buy) | M - Exercise or conversion exempt under rule 16b-3 | -23,491 | |
Mar 25/24 | Mar 21/24 | Garber Alan M | Direct Ownership | Common Stock | S - Open market or private sale | -19,205 | $24.01 |
Mar 25/24 | Mar 21/24 | Garber Alan M | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 23,491 | $19.57 |
Feb 27/24 | Feb 23/24 | Peterson Amy C. | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 82,121 | |
Feb 27/24 | Feb 23/24 | Aftab Dana | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 63,350 | |
Feb 27/24 | Feb 23/24 | Morrissey Michael | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 241,670 | |
Feb 27/24 | Feb 23/24 | Senner Christopher J. | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 82,121 | |
Feb 27/24 | Feb 23/24 | Hessekiel Jeffrey | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 63,350 | |
Feb 27/24 | Feb 23/24 | Haley Patrick J. | Direct Ownership | Common Stock | S - Open market or private sale | -47,020 | $21.45 |
Feb 27/24 | Feb 23/24 | Haley Patrick J. | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 63,350 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Cerevel Therapeutics Hold (OQ:CERE) |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |